Introduction
Organ transplantation is the preferred treatment of choice for patients with end-stage organ failure. However, the mortality and mobility associated with broad immunosuppression in transplant patients remains a significant barrier to the actual therapeutic potential of organ transplantation. The recent emergence of composite tissue transplantation, which is the treatment of choice for patients suffering from severe burns and trauma, presents new challenges and opportunities for long-term transplant survival without drug-associated toxicities. Induction of immune tolerance is essential for avoiding pathogenic immune responses to self-antigens and alloantigens. Tolerance is also an ideal method of weaning patients off immunosuppressive drugs. It has been well-established that regulatory T cells (Tregs) are critical for maintaining immune tolerance by suppressing both autoimmunity and alloimmunity. There are multiple cell types in the immune system that exhibit immunosuppressive properties. In addition to the much publicized CD4 + CD25 + Foxp3 + Tregs, CD8 + Tregs have emerged as another key player in immune regulation.
A B S T R A C T

CD8
+ T cells are regulatory T cells (Tregs) that suppress both alloimmunity and autoimmunity in many animal models. This class of regulatory cells includes the CD8 + CD28 -, CD8 + CD103 + , CD8 + FoxP3 + and CD8 + CD122 + subsets. The mechanisms of action of these regulatory cells are not fully understood; however, the secretion of immunosuppressive cytokines, such as interleukin (IL)-4, IL-10 and transforming growth factor beta (TGF-β) as well as the direct killing of target cells via Fas L/Fas and the perforin/granzyme B pathways have been demonstrated in various models. Further studies are necessary to fully understand the mechanisms underlying the suppressive eff ects of Tregs and to provide experimental support for potential clinical trials. We recently observed that CD8 + CD122 + Tregs more potently suppressed allograft rejection compared to their CD4 + CD25 + counterparts, supporting the hypothesis that CD8 + Tregs may represent a new and promising Treg family that can be targeted to prevent allograft rejection in the clinic. In this review, we summarize the progress in the fi eld during the past 7-10 years and discuss CD8 + Treg phenotypes, mechanisms of action, and their potential clinical applications; particularly in composite tissue transplants in burn and trauma patients.
Early studies showed that CD8 + T cells could suppress immune responses, thereby functioning as suppressor cells, [1, 2] and tremendous progress has occurred regarding their suppression of alloimmunity and mechanisms of action. For example, Liu et al., demonstrated that  CD8   +   CD28 -T cells inhibited T helper alloreactivity in an major histocompatibility complex (MHC) class I-restricted manner. [3] These CD8 + Tregs also induced xenoreactive CD4 + T-cell anergy. [4] Human CD8 + Tregs inhibited graft-versus-host disease (GVHD) in humanized mice. [5] Additionally, either donor-specific or induced CD8 + FoxP3 + Tregs facilitated skin allograft survival in certain models. [6] Moreover, antigen-induced CD8 + CD103
+ Tregs have been shown to suppress alloreactive effector T cell function. [7] More importantly, several recent studies have shown that CD8 + CD122 + T cells are also potent Tregs that inhibit both alloimmunity and autoimmunity.
[ 
CD28
-T cells, [3] which were generated by multiple rounds of in vitro allostimulation of peripheral blood mononucleocytes. These MHC class-I-restricted CD8 + CD28 -T cells induced xenoreactive human CD4 + T-cell anergy upon specific recognition of MHC class-I antigens. [4] [27] The induced, but not natural, CD8 + CD28 -Tregs expressed glucocorticoidinduced tumor necrosis factor receptor-related protein (GITR) and cytotoxic T-cell antigen 4 (CTLA4), whereas both Tregs expressed CD62L [27, 28] [ Figure 2 ]. Moreover, graft function was maintained with minimal or no immunosuppression in patients that had circulatory CD8 +
-Tregs. [29] The expansion of CD8 + CD28 -Tregs was associated with the reduced occurrence of acute or chronic rejection. [30] The adoptive transfer of CD8
Tregs from tolerized liver transplant recipients alleviated acute allograft rejection in rats. [31] 
Tregs
It has been shown that a CD8 + T cell population lacking CD44 but expressing CD103 produced transforming growth factor beta (TGF-β), inhibit CD4 + proliferation in vitro, and attenuate adoptively transferred ileitis in vivo, most likely by counteracting the proinflammatory role of the CD44 high subset of T cells. [33] Therefore, these CD8 + Tregs exhibit a naive T cell phenotype (CD8 Tregs increased in spontaneously tolerant recipients of a liver allograft. [34] Rapamycin not only promoted the in vitro generation of CD8 + CD103 + Tregs after allostimulation, but also enhanced their suppressive capacity. [35] However, a study by Feng et al., found that CD103 expression by CD8 + T cells was required for the destruction of islet allografts because CD8 + CD103 -T cells failed to infiltrate the islet grafts, [36] indicating that CD103 may be an effector but not a regulatory molecule. Therefore, further studies are necessary to better define the role of CD103 in alloreactive CD8 + T cell functions. Tregs in the recovery phase of EAE. [37] Brain DCs expressing the B7-H1 molecule recruit CD8 + CD122 + Tregs to the inflammatory site, which causes a decrease in the clinical EAE peak values. [38] Notably, CD8 + T cells increased the incidence of autoimmune Graves' hyperthyroidism in a mouse model, [40] suggesting that CD8 + CD122
+ T cells play an essential role in the inhibition of autoimmune hyperthyroidism. B6-Yaa mutant mice developed systemic lupus erythematous-like disease in association with a defect in CD8 +
CD122
+ Treg activity, suggesting that the Treg subset may be utilized to treat systemic lupus erythematous-like autoimmune disease.
[ CD25 is the α subunit of the IL-2 receptor. [41] 
Mechanisms of action
The mechanisms underlying CD8 + Treg suppression are not fully understood. However, multiple mechanisms are likely to be involved, including the killing or direct lysis of target cells, the induction of CD4 + T cell anergy, and the secretion of immunosuppressive cytokines and molecules. Different subsets of CD8 + Tregs may utilize distinct mechanisms. Studies by Cantor's group have demonstrated that perforin-mediated cytotoxicity is required for the suppressive activity of Qa-1-restricted CD8 + Tregs; [42] whereas, others have shown that CD11c + CD8 + Tregs can directly kill activated CD4 + T cells through the Fas ligand-Fas death pathway [43] [ Figure 2 ]. CD8 + CD28 -Tregs induced xenoreactive human CD4 + T-cell anergy [4] and also downregulated expression of the costimulatory molecules CD80/CD86 on APCs, [23] which indirectly block T cell priming by APCs. TGF-β expanded CD8 + CD103 + Tregs displayed cytotoxicity towards allospecific effector T cells through cell-to-cell contact.
[ + Th cell anergy and suppressed the differentiation of IFN-γ-producing effector CD8 + CTL. [45] The mechanisms of action for CD8 + CD122 + Treg suppression are also not well-defined. As shown in Figure  2 , IL-10 produced by CD8 + CD122
+ Tregs appears to be a primary mechanism responsible for suppression. [9, 17, 46] Endharti et al., presented the first data showing that CD8 + CD122 + Tregs suppressed IFN-γ production and the proliferation of CD8 + T cells by producing IL-10 in vitro.
[9] CD8 + Tregs also recognized activated T cells via the interaction of the MHC class I-αβ TCR and regulated target T cells by producing IL-10. [46] We also observed that the suppression of allograft rejection by IL-10-deficient CD8 + CD122
+ Tregs was largely diminished.
[17] Activated CD8 + CD122
+ Tregs from RasGRP1(-/-) mice synthesized IL-10 and inhibited the proliferation of CD8 + CD122 -T cells.
[10] However, IL-10 did not account for all mechanisms underlying CD8 + CD122 + Treg suppression.
[17] Other mechanisms, in addition to IL-10 production, may be involved in CD8 + CD122
+ Treg suppression. In particular, CD8 +
CD122
+ Tregs also released IFN-γ and TGF-β that suppressed CD4 + T cell activation.
[16] It remains to be determined whether the perforin/granzyme B pathway is also involved in regulating effector T cells by CD8 + CD122 + Tregs. Despite these findings, further studies are required to fully identify the mechanisms responsible for the suppression of alloimmunity or autoimmunity. Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8 + suppressor T cells. PLoS One 2011;6:e28948.
Conclusion
